Silence Therapeutics (NASDAQ:SLN) Trading Down 0.7% – Should You Sell?

Silence Therapeutics PLC Sponsored ADR (NASDAQ:SLN) shares were down 0.7% on Wednesday . The stock traded as low as $5.65 and last traded at $5.87. Approximately 384,699 shares traded hands during trading, an increase of 26% from the average daily volume of 304,155 shares. The stock had previously closed at $5.91.

Analysts Set New Price Targets

Several equities research analysts have recently commented on SLN shares. Wall Street Zen raised Silence Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, November 8th. Weiss Ratings restated a “sell (d-)” rating on shares of Silence Therapeutics in a report on Wednesday, October 8th. Four analysts have rated the stock with a Buy rating and two have assigned a Sell rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Hold” and an average target price of $32.60.

Silence Therapeutics Price Performance

The firm has a market cap of $277.24 million, a PE ratio of -4.35 and a beta of 1.32. The business has a fifty day moving average price of $6.35 and a two-hundred day moving average price of $5.96.

Silence Therapeutics (NASDAQ:SLN) last announced its quarterly earnings data on Thursday, November 6th. The company reported ($0.45) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.40) by ($0.05). Silence Therapeutics had a negative return on equity of 61.76% and a negative net margin of 254.25%.The business had revenue of $0.16 million during the quarter, compared to analysts’ expectations of $3.28 million. As a group, sell-side analysts forecast that Silence Therapeutics PLC Sponsored ADR will post -1.77 EPS for the current fiscal year.

Institutional Trading of Silence Therapeutics

Institutional investors have recently made changes to their positions in the stock. GAMMA Investing LLC grew its position in Silence Therapeutics by 134.1% during the second quarter. GAMMA Investing LLC now owns 8,333 shares of the company’s stock valued at $48,000 after purchasing an additional 4,773 shares in the last quarter. EHP Funds Inc. purchased a new stake in Silence Therapeutics in the 3rd quarter worth approximately $55,000. Beacon Pointe Advisors LLC acquired a new stake in shares of Silence Therapeutics during the 2nd quarter valued at $67,000. Evelyn Partners Investment Management Services Ltd grew its holdings in shares of Silence Therapeutics by 481.3% during the 2nd quarter. Evelyn Partners Investment Management Services Ltd now owns 14,334 shares of the company’s stock valued at $77,000 after acquiring an additional 11,868 shares in the last quarter. Finally, Massar Capital Management LP purchased a new position in shares of Silence Therapeutics during the 2nd quarter valued at $115,000. 98.73% of the stock is currently owned by institutional investors and hedge funds.

Silence Therapeutics Company Profile

Silence Therapeutics plc is a clinical-stage biotechnology company focused on the discovery and development of ribonucleic acid interference (RNAi) therapeutics. Leveraging its proprietary EnCore lipid nanoparticle delivery platform, the company aims to silence disease-causing genes in the liver and other tissues. Silence’s technology is designed to enhance targeted delivery of small interfering RNA (siRNA) molecules, with the goal of achieving durable therapeutic effects and improved safety profiles compared with traditional drug modalities.

The company’s lead product candidates include SLN360, an siRNA therapeutic designed to reduce lipoprotein(a) levels for cardiovascular risk reduction, and SLN124, aimed at treating hereditary hemochromatosis and beta-thalassemia by modulating iron metabolism.